Rightmove Shares Rise on REA Group Bid Interest
By Anthony O. Goriainoff
Rightmove shares rose Monday, leading the FTSE 100 index risers, after Australia's REA Group said it was considering a cash-and-share offer for the U.K. company that would create a combined company worth $25 billion.
Shares at 0722 GMT were up 130.80 pence, or 24%, at 686.60 pence, marking its biggest percentage move since 2009.
The Australian real-estate advertiser said Monday that it had yet to speak with U.K.-listed Rightmove over any offer and wasn't certain of making a bid within the 28-day deadline specified by the U.K.'s takeover code.
Rightmove didn't immediately respond to requests for comment when approached by Dow Jones Newswires.
REA said it saw a significant opportunity to create shareholder value by combining both advertisers and highlighted the potential for strong margins, significant cash generation, and shareholder returns. It didn't give any financial details.
REA is 61% owned by News Corp., the parent company of Dow Jones & Co., publisher of The Wall Street Journal and Dow Jones Newswires.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 02, 2024 03:43 ET (07:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks